Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

CD9 expression is not a prognostic factor in human osteosarcoma.

Bernd Kubista1, Boban M Erovic, Helmut Klinger

  • 1Department of Orthopaedics, Waehringergürtel 18-20, A-1090 Vienna, Austria.

Cancer Letters
|May 18, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Pilot Study: Reimagining Facial Tumor Resection by Introducing the Tau Incision in Head and Neck Surgery.

Plastic and reconstructive surgery. Global open·2026
Same author

Systematic Analysis of Surgical Management in Traumatic Cervical Spondyloptosis.

Zeitschrift fur Orthopadie und Unfallchirurgie·2026
Same author

Piwil-2 represents a poor prognosticator in Merkel cell carcinomas that regulates oncoproteins, cell cycle arrest and SOX-2 expression.

Scientific reports·2025
Same author

Impact of UV Exposure and Incidence of Merkel Cell Carcinoma Between 1990 and 2018 in Austria.

Cancers·2025
Same author

Practice Patterns in Management of Low- to Intermediate-Grade Salivary Gland Carcinoma: A Multi-Institutional Study.

Laryngoscope investigative otolaryngology·2025
Same author

[Literature review on kyphoplasty as a treatment for osteoporotic fractures of the spine].

Orthopadie (Heidelberg, Germany)·2025

CD9 expression, also known as Motility-Related Protein-1 (MRP-1), does not appear to predict chemotherapy response or survival in osteosarcoma patients. This contrasts with its role in other solid tumors, suggesting CD9 is not a useful prognostic marker for osteosarcoma.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • CD9 (Motility-Related Protein-1) is involved in cell adhesion and signaling, with its downregulation linked to tumor progression in solid tumors.
  • While osteosarcoma prognosis has improved, identifying non-responders and predicting chemotherapy response remains a challenge.
  • There is a need for biomarkers to stratify osteosarcoma patients and predict treatment outcomes at the time of biopsy.

Purpose of the Study:

  • To investigate the impact of CD9 expression on chemotherapy response and survival in osteosarcoma patients.
  • To determine if CD9 can serve as a prognostic factor for osteosarcoma.

Main Methods:

  • Immunohistochemical examination of CD9 expression in 52 high-grade osteosarcoma patient samples.
  • Correlation of CD9 expression status with histologic response to chemotherapy.

Related Experiment Videos

  • Analysis of the association between CD9 expression and 5-year disease-free survival (DFS) and 5-year overall survival (OS).

    • Main Results:

    • CD9 expression was detected in 42% of osteosarcoma cases.
    • No statistically significant correlation was found between CD9 expression and response to chemotherapy.
    • Disease-free survival and overall survival rates did not significantly differ between CD9-positive and CD9-negative osteosarcoma tumors.

    Conclusions:

    • CD9 expression is unlikely to provide additional prognostic information for osteosarcoma patients.
    • Unlike in other solid tumors, CD9 does not appear to be a reliable biomarker for predicting chemotherapy response or survival in osteosarcoma.
    • Further research may be needed to identify reliable prognostic markers for osteosarcoma.